Atripla oral liquid

Atripla oral liquid is an extemporaneously prepared formulation of the fixed-dose combination tablet Atripla, developed for evaluation by the University of Alabama at Birmingham. It contains three antiretroviral agents: efavirenz, emtricitabine, and tenofovir disoproxil fumarate. This formulation was designed to provide an alternative for patients with HIV-1 infection who have difficulty swallowing solid oral dosage forms. The drug works by inhibiting the HIV-1 reverse transcriptase enzyme through two distinct mechanisms: emtricitabine and tenofovir act as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that cause chain termination, while efavirenz acts as a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds allosterically to the enzyme. The University of Alabama at Birmingham conducted bioequivalence studies to compare this liquid formulation, created by crushing commercial tablets into a solution, against the standard tablet form.

Brand names

Atripla

Other names

efavirenz + emtricitabine + tenofovir disoproxil fumarate oral liquidextemporaneously prepared oral liquid formulation of Atripla